3O8.F Omeros Corporation

Healthcare Biotechnology Frankfurt Exchange
15.40 EUR
Close of Nov 11, 2026
6.14 18.05
Market cap
EUR 1.11B
P/E
14.3x
P/B
3.77x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 3O8.F undervalued?

Graham number
Price15.40
Graham value9.96
Premium54.6%

3O8.F trades 54.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Omeros Corporation fundamental analysis

No fundamental analysis for Omeros Corporation yet.

Omeros Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also deve…

Full company profile